1. Low-Dose Azacitidine (AZA) for Treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapse after Allogeneic Hematopoietic Cell Transplant (HCT) 
Masumi Ueda, MD, Hillard M. Lazarus, MD, Brenda Cooper, MD, Paolo Caimi, MD, Richard Creger, PharmD, Jane A. Little, MD, Linda Baer, CNP, Lauren Brister, CNP, AOCNP, Ehsan Malek, MD, Leland Metheny, MD, Benjamin Tomlinson, MD, Stan L. Gerson, MD, Betul Oran, MD, Marcos de Lima, MD 
Biology of Blood and Marrow Transplantation 
Volume 22, Issue 3, Pages S212-S213 (March 2016)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1 Survival by AZA response
Biology of Blood and Marrow Transplantation  , S212-S213DOI: ( /j.bbmt )
Copyright © Terms and Conditions